Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage

Shay Menascu, Aviva Fattal-Valevski, Adi Vaknin-Dembinsky, Ron Milo, Keren Geva, David Magalashvili, Mark Dolev, Shlomo Flecther, Alon Kalron, Shmulik Miron, Chen Hoffmann, Roy Aloni, Michael Gurevich, Anat Achiron

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Effect of natalizumab treatment on the rate of No Evidence of Disease Activity in young adults with multiple sclerosis in relation to pubertal stage'. Together they form a unique fingerprint.

Medicine & Life Sciences